BARCELONA -- Rivaroxaban (Xarelto) appeared risky for treating atrial fibrillation in rheumatic heart disease, the INVICTUS trial showed. Rivaroxaban increased the composite of stroke, systemic ...

Adding the oral anticoagulant rivaroxaban (Xarelto, Janssen) to standard therapy after myocardial infarction (MI) or unstable angina significantly reduced the risk for cardiovascular mortality, data ...

Dec 21 (Reuters) - Older adults taking Bayer AG's (BAYGn.DE), opens new tab blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious ...

Contrary to expectations, vitamin K antagonists (VKAs) reduced the risk for ischemic stroke and death compared with the factor Xa inhibitor rivaroxaban (Xarelto, Janssen) in patients with rheumatic ...

The Food and Drug Administration has approved Bayer and J& J (NYSE: JNJ) drug Xarelto to treat atrial fibrillation, or abnormal heart rhythm. Earlier this year, Xarelto was approved for use as an anti ...

Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th ...

The Food and Drug Administration approved the use of the blood thinner drug Xarelto to treat patients with atrial fibrillation, or irregular heartbeat, reports Reuters. Xarelto, first approved in 2011 ...

Observational data suggest that subclinical leaflet thrombosis may occur with bioprosthetic valves and that the risk can be reversed by anticoagulation. Current guidelines, based mainly on expert ...

Lupin has received the Food and Drug Administration’s green light for rivaroxaban tablets, in 10 mg, 15 mg and 20 mg, which is the generic of Janssen’s Xarelto. This product will be manufactured at ...

A win in patent court in Europe last October was a pleasant surprise for Bayer, giving its heart drug Xarelto an additional two years of exclusivity—all the way to 2026. But the generics ship already ...